Health care stocks were declining Thursday afternoon, with the NYSE Health Care Index shedding 0.4% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) fell 1.1%.
In corporate news, Eli Lilly's (LLY) tirzepatide injection products Zepbound and Mounjaro are no longer in shortage, the US Food and Drug Administration said Thursday. Eli Lilly shares were down 0.8%.
Omeros (OMER) shares surged 44% after it said Thursday that its trial of narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy met its primary endpoint in overall survival.
Aquestive Therapeutics (AQST) shares jumped 5.6% after it said Thursday that its Libervant buccal film has received seven years of orphan drug exclusivity from the US Food and Drug Administration to treat seizure clusters in patients with epilepsy ages two to five.
Comments